Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87896
Title:
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Authors:
Fallowfield, Lesley J; Leaity, Samantha K; Howell, Anthony ( 0000-0002-3879-5991 ) ; Benson, Sarah; Cella, David
Abstract:
Existing quality of life instruments do not include adequate items to measure the side effects and putative benefits of hormonal treatments given in breast cancer. We report the development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT-B). The FACT-ES (FACT-B plus ES) was tested initially on 268 women with breast cancer receiving endocrine treatments. Alpha coefficients for all subscales demonstrated good internal consistency (range alpha = 0.65-0.87). Test-retest reliability of the ES indicated good stability (r = 0.93, p < 0.001). Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns. Most frequently reported symptoms were loss of sexual interest (31%), weight gain (25%), and hot flushes (24%). Significant differences were found between treatment groups for hot flushes and vaginal dryness. Two assessments of the instrument's responsiveness to change were made; 32 women in a clinical trial of endocrine therapy and 18 women without breast cancer taking HRT completed the FACT-ES at baseline, 4, 8, and 12 weeks. Trial patients reported significantly more symptoms at 8 and 12 weeks than at baseline. Women taking HRT reported significantly fewer or less severe symptoms than at baseline. In conclusion the FACT-ES has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy.
Affiliation:
CRC Psychosocial Oncology Group, Department of Oncology, University College London Medical School, UK. I.fallowfield@ucl.ac.uk
Citation:
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. 1999, 55 (2):189-99 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
May-1999
URI:
http://hdl.handle.net/10541/87896
DOI:
10.1023/A:1006263818115
PubMed ID:
10481946
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFallowfield, Lesley Jen
dc.contributor.authorLeaity, Samantha Ken
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorBenson, Sarahen
dc.contributor.authorCella, Daviden
dc.date.accessioned2009-12-14T15:08:49Z-
dc.date.available2009-12-14T15:08:49Z-
dc.date.issued1999-05-
dc.identifier.citationAssessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. 1999, 55 (2):189-99 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid10481946-
dc.identifier.doi10.1023/A:1006263818115-
dc.identifier.urihttp://hdl.handle.net/10541/87896-
dc.description.abstractExisting quality of life instruments do not include adequate items to measure the side effects and putative benefits of hormonal treatments given in breast cancer. We report the development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT-B). The FACT-ES (FACT-B plus ES) was tested initially on 268 women with breast cancer receiving endocrine treatments. Alpha coefficients for all subscales demonstrated good internal consistency (range alpha = 0.65-0.87). Test-retest reliability of the ES indicated good stability (r = 0.93, p < 0.001). Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns. Most frequently reported symptoms were loss of sexual interest (31%), weight gain (25%), and hot flushes (24%). Significant differences were found between treatment groups for hot flushes and vaginal dryness. Two assessments of the instrument's responsiveness to change were made; 32 women in a clinical trial of endocrine therapy and 18 women without breast cancer taking HRT completed the FACT-ES at baseline, 4, 8, and 12 weeks. Trial patients reported significantly more symptoms at 8 and 12 weeks than at baseline. Women taking HRT reported significantly fewer or less severe symptoms than at baseline. In conclusion the FACT-ES has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshEvaluation Studies as Topic-
dc.subject.meshFemale-
dc.subject.meshHormone Replacement Therapy-
dc.subject.meshHumans-
dc.subject.meshMegestrol Acetate-
dc.subject.meshMenopause-
dc.subject.meshMiddle Aged-
dc.subject.meshNitriles-
dc.subject.meshPilot Projects-
dc.subject.meshQuality of Life-
dc.subject.meshQuestionnaires-
dc.subject.meshTamoxifen-
dc.subject.meshTime Factors-
dc.subject.meshTriazoles-
dc.titleAssessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.en
dc.typeArticleen
dc.contributor.departmentCRC Psychosocial Oncology Group, Department of Oncology, University College London Medical School, UK. I.fallowfield@ucl.ac.uken
dc.identifier.journalBreast Cancer Research and Treatmenten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.